The first small molecule inhibitor of MIF, ISO-1, provided proof of concept for significantly increasing the survival of mice with sepsis (166), reducing disease severity in mouse models of SLE (167), and delaying onset in a mouse model of autoimmune diabetes (168). Here, MIF is linked to systemic lupus erythematosus.